Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Kazakhstan has been experiencing significant growth in recent years.
Customer preferences: Kazakhstan's population is aging, which is driving the demand for pharmaceutical products. Additionally, the country's increasing incidence of chronic diseases such as diabetes and cardiovascular disease is also contributing to the growth of the pharmaceutical market.
Trends in the market: One of the major trends in the pharmaceutical market in Kazakhstan is the rising demand for generic drugs. This is due to the fact that generic drugs are more affordable than their branded counterparts, which is particularly important in a country where a significant portion of the population lives below the poverty line. Another trend in the market is the increasing focus on research and development, as pharmaceutical companies seek to develop innovative new drugs to meet the needs of the country's aging population.
Local special circumstances: Kazakhstan has a relatively underdeveloped healthcare system, which means that there is significant room for growth in the pharmaceutical market. Additionally, the country's government has been actively working to improve healthcare access and quality, which is expected to further drive demand for pharmaceutical products.
Underlying macroeconomic factors: Kazakhstan's growing economy and increasing middle class are also contributing to the growth of the pharmaceutical market. As more people are able to afford healthcare, demand for pharmaceutical products is expected to continue to rise. Additionally, the country's strategic location at the crossroads of Europe and Asia makes it an attractive market for pharmaceutical companies looking to expand their reach in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)